Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer
Open Access
- 1 January 2021
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 18 (3) , 660-671
Abstract
Background: Numerous studies have suggested that differentially expressed miRNAs may be promising diagnostic markers for pancreatic cancer (PC), but the results are inconsistent. We aimed to summarize the diagnostic accuracy of circulating miRNAs, carbohydrate antigen 19-9 (CA19-9), and the combination of miRNAs and CA19-9.Keywords
All Related Versions
This publication has 56 references indexed in Scilit:
- Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinomaWorld Journal of Surgical Oncology, 2013
- MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease ControlsClinical Cancer Research, 2013
- Combined Serum CA19-9 and miR-27a-3p in Peripheral Blood Mononuclear Cells to Diagnose Pancreatic CancerCancer Prevention Research, 2013
- Screening for Pancreatic CancerAnnals of Surgery, 2013
- Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic CancerClinical Chemistry, 2012
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancerInternational Journal of Cancer, 2011
- MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of DiseaseCancer Prevention Research, 2009
- Exploring sources of heterogeneity in systematic reviews of diagnostic testsStatistics in Medicine, 2002
- Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test dataStatistics in Medicine, 2002